Information Provided By: 
Fly News Breaks for April 22, 2019
RCKT
Apr 22, 2019 | 16:31 EDT
Baird analyst Madhu Kumar initiated Rocket Pharmaceuticals with an Outperform rating and a $28 price target, with the analyst saying that lentiviral gene therapy RP-L102 for the treatment of Fanconi anemia type A, which is currently in Phase 1/2 with data expected in the second half of the year, could serve as a "key catalyst" for the stock.
News For RCKT From the Last 2 Days
There are no results for your query RCKT
